Viatris (VTRS) Q2 2026 Earnings Preview

Report Date: Thursday, August 6, 2026 (before market open) | Call: 8:30 a.m. ET

---

1. Setup Into the Print

VTRS shares have run up meaningfully since the Q1 report, rising from roughly $15 in early May to around $17.6-17.7 today, helped by a clean Q1 beat, a positive FDA approval right before earnings, and a string of sell-side price target increases (Barclays to $22, UBS to $20, JPMorgan to $18). Expectations are now higher heading into Q2, which raises the bar for what counts as a "good" quarter.

Street estimates are roughly centered on ~$3.5 billion in revenue and adjusted EPS in the mid-$0.50s for the quarter, consistent with management's own guidance phasing (revenue and earnings are expected to skew toward the second half of the year).

2. What Happened Last Quarter (the Baseline)

Q1 2026 was a strong, "clean" quarter that reset investor confidence. Viatris delivered total revenues of $3.5 billion, representing 8% reported growth compared to first quarter 2025, and U.S. GAAP net earnings of $176 million, with total revenues up 3% operationally and adjusted EBITDA up 10% operationally, demonstrating solid operating leverage. Adjusted EPS was $0.59 per share, up 18% on a reported basis and up 14% on an operational basis compared to the first quarter of 2025.

The standout driver was China: the company delivered a very strong quarter in Greater China with growth accelerating ahead of expectations at 18% year-over-year, driven by favorable market fundamentals, cumulative selling and marketing investments, and growth across all channels, with e-commerce sales more than doubling versus the prior year. Management raised its internal China growth expectation for the year — from low-single digits at the start of the year to now mid- to high-single-digit growth in China, while flagging that policy risk remains dynamic and unpredictable. By contrast, Europe net sales declined about 1% due to softer market conditions, competitive pressure on Dymista and supply constraints, while emerging markets were flat, held back by supply constraints in the lower-margin ARV portfolio, and JANZ fell about 2% on competition in Australia and Japanese price regulation.

Importantly, the company reaffirmed its full-year 2026 financial guidance, and on the call management struck a confident, "beat-and-hold" tone rather than raising guidance outright: "Because of the strong momentum of the first quarter results, we believe we are well positioned to meet or potentially exceed our expectations for the remainder of the year."

3. FY2026 Guidance — The Scorecard for Q2

Metric	FY26 Guidance Range	Midpoint
Total Revenues	$14.45B – $14.95B	$14.70B
Adjusted EBITDA	$4.15B – $4.45B	$4.30B
Adjusted EPS	$2.33 – $2.47	$2.40
FCF (ex. transaction/restructuring costs)	$1.95B – $2.35B	$2.15B

Viatris is not providing forward-looking guidance for U.S. GAAP net earnings or diluted EPS, but U.S. GAAP net cash provided by operating activities for 2026 is estimated to be between $1.7 billion and $2.0 billion, with a midpoint of approximately $1.85 billion. On the Q1 call, CFO Paul Campbell noted that total revenues, adjusted EBITDA and adjusted EPS are still expected to be weighted to the second half at approximately 52% of the full-year outlook, reflecting normal seasonality and new product launch timing, implying a Q2 print that should look more like a "normal" transition quarter than Q1's outsized China-driven beat. Investors should watch closely whether management raises guidance this quarter given the Q1 upside, or continues to bank the beat as a cushion against H2 risks (Europe competition, ARV supply, FX).

4. Key Operating Questions for the Quarter

• Is Greater China durability intact? The 18% operational growth in Q1 was well above trend. Watch for confirmation that the e-commerce/retail shift (away from hospital channels more exposed to volume-based procurement policy) is sustaining momentum into Q2, and any fresh commentary on China healthcare policy risk.
• North America generics/complex generics — new product launches (estradiol, Breyna) drove Q1 strength; watch for continued contribution and progress on the $450–550 million of new product revenue targeted for 2026 (only ~$71 million was recognized in Q1, so the ramp is heavily H2-weighted).
• ARV supply constraints in Emerging Markets — management said in Q1 it was mitigating via alternate sourcing and had "baked in" the risk to guidance; an update on resolution timing matters for Emerging Markets segment trends.
• Europe and JANZ softness — Dymista competition, generic pricing pressure, and Japan price regulation were headwinds in Q1; look for signs of stabilization or further deterioration.
• Margins — Q1 adjusted gross margin was flat at 56%, with OpEx favorability from cost discipline and early restructuring savings; investors will want proof that EBITDA leverage (10% operational growth on 3% revenue growth in Q1) continues.

5. Pipeline Catalysts — Several Already Delivered Since Q1

Viatris entered the year with six anticipated regulatory decisions, and several have now cleared:

• Gwyn Lo (formerly the low-dose estrogen weekly contraceptive patch) — the FDA approved the product on July 29, 2026, just ahead of its July 30 PDUFA date. It is a once-weekly combined hormonal contraceptive patch, and Viatris expects it to be commercially available by the end of 2026 — an important near-term launch for the women's health franchise, though the approved label carries a BMI-under-30 restriction that limits the addressable population.
• Fast-acting meloxicam (MR-107A-02) for moderate-to-severe acute pain — NDA accepted by FDA; management expects opioid-sparing language to be included in the label, subject to FDA review and discussion, and is building a specialty sales force of roughly 150–200 reps for the launch. A PDUFA decision is still expected in the second half of 2026.
• Phentolamine ophthalmic solution (MR-141) for presbyopia — sNDA has an assigned PDUFA goal date of October 17, 2026 (per Q1 commentary).
• Pitolisant in Japan (OSAS and narcolepsy) — J-NDAs under PMDA review, with decisions expected in the second half of 2026.
• Nefecon (VR-205) in Japan — Viatris announced in early July that the Phase 3 study in Japanese patients with IgA nephropathy met its primary and key secondary endpoints and was well tolerated, consistent with the global profile — a positive readout that should support filing.
• Longer-dated catalysts: selatogrel (Phase III SOS-AMI, enrolling ~1,200 patients/month, full enrollment targeted by end of 2026) and cenerimod (Phase III OPUS-1/2 in SLE, fully enrolled, data expected first half of 2027) remain the bigger long-term innovative-pipeline optionality, with management reiterating a longer-term target of 4% organic revenue growth by 2030 (per the March 2026 Investor Day).

Given this cadence of newsflow since Q1, the call is likely to include incremental updates/timing on meloxicam's PDUFA date and label, Gwyn Lo's commercial launch plan, and Japan approvals for pitolisant.

6. Capital Allocation & Corporate Items

• Viatris continues to expect more than $2.5 billion of cash available for deployment in 2026, and returned $140 million to shareholders via dividend in Q1 alone.
• Biocon exit: Mylan (a Viatris subsidiary) fully monetized its legacy ~5.64% Biocon stake in mid-July via a ~$363 million block sale, removing a long-standing overhang and adding to available capital following expiry of a lock-in from the earlier Biocon Biologics transaction.
• Restructuring/cost savings: the enterprise-wide strategic review is targeting $650 million in total cost savings (with up to $250 million of reinvestment) over three years, including a workforce reduction of up to ~10%; management said on the Q1 call it remains on track to deliver roughly $120 million of savings this year, and that this is already showing up as EBITDA leverage.
• CFO transition: Doretta Mistras departed as CFO; Paul Campbell (longtime Chief Accounting Officer/Controller) stepped in as interim CFO. Management stated explicitly that investors should expect no change to capital allocation or financial policy as a result.
• Business development: management reiterated a preference for in-market, accretive, bolt-on M&A over early-stage R&D risk, with the war chest earmarked for opportunities that are "the right size" for Viatris rather than being absorbed by larger pharma.

7. Risks / Overhangs to Watch on the Call

• Generic drug tariffs: President Trump announced in late July that imported generics will remain tariff-free through August 2026, before phasing to a 100% tariff in August 2028 and 200% a year later. This is a multi-year risk rather than an immediate Q2 issue, but Viatris derives a meaningful share of its U.S. generics from imported manufacturing, so expect analyst questions on onshoring plans and exposure.
• China policy risk: management has been explicit that volume-based procurement/pricing policy changes remain unpredictable, even as they expressed confidence of no policy shift this year.
• Manufacturing/quality: Q1 results already absorbed costs tied to a fire at the Nashik manufacturing facility (inventory/fixed-asset write-offs), and the ARV supply constraint issue in Emerging Markets is not yet fully resolved — watch for updates on both.
• FX: management flagged an incremental ~1% currency tailwind to revenue and EBITDA if rates hold, a modest but real swing factor versus guidance.
• Rising bar: with the stock up meaningfully post-Q1 and price targets raised across the Street, a merely "in-line" quarter without a guidance raise could disappoint given how much good news (Gwyn Lo approval, Nefecon Japan data, Biocon monetization) has already been absorbed by the market ahead of the print.

8. Bottom Line

Q2 is less about a single headline number and more about durability: can Viatris show that the China acceleration, North America generics strength, and pipeline execution seen in Q1 are sustainable trends rather than a one-quarter phenomenon, while offsetting known drags in Europe, JANZ, and ARV supply? With guidance reaffirmed (not raised) after a strong Q1, and consensus already expecting a step down in growth rates for Q2 in line with 52%-second-half-weighted guidance, the key swing factors for the stock reaction will likely be: (1) any language on raising full-year guidance, (2) fresh detail on the new-product-revenue ramp toward the $450–550 million target, (3) updated timing/label color on fast-acting meloxicam and the Gwyn Lo launch, and (4) management's read on tariff and China-policy risk heading into 2027 planning.